Pfizer (PFE) Stock Forecast & Price Target

Pfizer is viewed favorably because its scale, with roughly $60 billion in annual sales, is supported by a diversified global portfolio of prescription drugs and vaccines, including Prevnar 13, Vyndamax, and Eliquis, while international markets contribute about 40% of revenue and emerging markets add further growth potential. Its outlook is also strengthened by execution that continues to exceed expectations, an estimated 2027 EPS of $2.81, and a dividend yield of 6.6%, suggesting attractive cash generation alongside a modest valuation of about 9.3x earnings. Longer term, the company’s return to growth by the end of the decade is being supported by pipeline progress in pneumococcal vaccines, amylin analogs, and prostate cancer assets, which could offset patent-related pressures over the next 2 years.

Pfizer is facing a deteriorating near-term fundamental picture as its 2026 guidance already embeds an expected ~$1.1B year-over-year revenue drag from products losing exclusivity, pressuring growth and mix. The outlook is further weakened by likely Prevnar softness in 3Q26 from lower vaccination rates, fewer births, and U.S. vaccine policy, while commercial execution risks around Padcev, Comirnaty, Paxlovid, and Nurtec could leave key revenue streams underwhelming. With positive pipeline data needed to offset post-LOE erosion and added macro threats from drug-pricing reform and tariff policy, the stock’s earnings visibility and investor sentiment remain fragile.